Kenneth G Ferguson

Licenses:

New Jersey - Active 2011

Office:

Ferguson Law Firm, L.L.C.

ISLN:

916562319

Admitted:

1997

University:

University of Missouri, B.S.

Law School:

St. Louis University, J.D.

Specialties:

Urology

Work:

Sutter Medical GroupSutter Medical Group Urology
2030 Sutter Pl STE 1000, Davis, CA 95616
530-7505995 (phone), 530-7505905 (fax)

Education:

Medical School
University of Virginia School of Medicine
Graduated: 1997

Procedures:

Cystoscopy
Cystourethroscopy
Vaginal Repair
Bladder Repair
Circumcision
Kidney Stone Lithotripsy
Nephrectomy
Prostate Biopsy
Transurethral Resection of Prostate
Urinary Flow Tests
Vasectomy

Conditions:

Erectile Dysfunction (ED)
Prostatitis
Urinary Incontinence
Urinary Tract Infection (UT)
Benign Prostatic Hypertrophy

Languages:

English
Spanish

Description:

Dr. Ferguson graduated from the University of Virginia School of Medicine in 1997. He works in Davis, CA and specializes in Urology. Dr. Ferguson is affiliated with Sutter Davis Hospital.

Specialties:

Family Medicine

Education:

The University of Texas at Houston (1988)

Location:

Bentonville, Arkansas

Industry:

Retail

Position:

Company Commander at US Army

Location:

US Military Posts in the Pacific

Industry:

Aviation & Aerospace

Work:

Work:

Self-Employed

Oct 2010 to 2000
Owner/Operator NL Olson & Associates
Port Orchard, WA
Jun 2007 to Dec 2009
Civil Engineering Design Technician D&H Specialty Contracting
Port Orchard, WA
Feb 2004 to Oct 2008
Construction Engineer/Superintendant Master, Mates and Pilots Association
Seattle, WA
Mar 1994 to May 2004
Ship's Chief Officer Benair Aviation Inc
Renton, WA
Feb 1985 to Mar 1994
Avionics Manager/Chief Inspector

Education:

Olympic College
2005
Engineering Arts & Science Pacific Maritime Institute of Graduate Studies
2001
Diploma Clover Park Technical College-Aviation Maintenance & Repair Technology
1989
Diploma ITT Technical College
1985
Associates in Electronic Engineering Technology

Location:

United States

Location:

Chicago, Illinois

Industry:

Computer Software

Location:

Rogers, Arkansas

Industry:

Legal Services

Location:

United States

Location:

United States

About:

Born:

1921

Died:

2011

Work:

Business category:

Cheese

Position:

President

Education:

Studied at:

Sydney Grammar School • University of Sydney

Academic degree:

Professor

Specialty:

Vet

Skills & Activities:

Award:

Recipient of the Centenary Medal

Skill:

Scientific

US Patent:

20010053780, Dec 20, 2001

Filed:

Apr 13, 2001

Appl. No.:

09/834442

Inventors:

John Whitaker - Woodinville WA,
Inigo Tejada - Madrid,
Kenneth Ferguson - Bothell WA,

International Classification:

A61K031/4985

US Classification:

514/250000

Abstract:

The present invention relates to phosphodiesterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic quanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 10 mg unit dosage are useful for the treatment of sexual dysfunction by daily administration of the PDE5 inhibitor. The articles of manufacture described herein are characterized by PDE5 inhibition, and accordingly, provide a benefit in therapeutic areas where inhibition of PDE5 is desired, especially erectile dysfunction, with minimization or elimination of adverse side effects resulting from inhibition of other phosphodiesterase enzymes and with an improvement of -vascular conditioning.

US Patent:

20030144296, Jul 31, 2003

Filed:

Jan 14, 2003

Appl. No.:

10/341664

Inventors:

John Whitaker - Woodinville WA,
Inigo Tejada - Madrid,
Kenneth Ferguson - Bothell WA,

Assignee:

Lilly ICOS LLC

International Classification:

A61K031/498
A61K031/496
A61K031/519

US Classification:

514/249000, 514/252160, 514/262100, 514/250000

Abstract:

The present invention relates to phosphodiesterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 10 mg unit dosage are useful for the treatment of sexual dysfunction by daily administration of the PDE5 inhibitor. The articles of manufacture described herein are characterized by PDE5 inhibition, and accordingly, provide a benefit in therapeutic areas where inhibition of PDE5 is desired, especially erectile dysfunction, with minimization or elimination of adverse side effects resulting from inhibition of other phosphodiesterase enzymes and with an improvement of vascular conditioning.